Compare Illumina, Inc. (ILMN) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Invesco Preferred ETF — how do they compare? Illumina, Inc. trades at $189.49 (market cap $27.94B), while Invesco Preferred ETF trades at $10.8. The key difference: Illumina, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | PGX | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | — |
52-Week High | $194.33 | $11.87 |
52-Week Low | $91.00 | $10.81 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
PGX trades at $10.81, down 0.46% on the day, with a bearish technical outlook from moving averages and neutral oscillators. The stock shows uniform support and resistance at $11. Recent corporate actions include upcoming dividends of $0.06 and $0.05 scheduled for July and June 2026, respectively. Financial ratios such as P/E, P/S, and ROE are not provided, limiting fundamental assessment.
The outlook for PGX is cautious due to bearish technical signals and negative media sentiment highlighting poor returns and limited downside protection. Investment opportunities may arise from dividend income, but risks include market volatility and structural subordination issues. Investors should weigh the income potential against significant downside risks in volatile conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
